Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc…
By A. Tefferi, J. Thiele, A. Orazi, H. Kvasnicka, T. Barbui, C. Hanson, G. Barosi, S. Verstovsek, G. Birgegard, R. Mesa and 9 more. Blood, 2007
910 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/18197de817aae90a1eee19ef3c509399d7638348
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Caramella
- E. Pungolino
- M. Cazzola
- M. Lazzarino
- P. Guglielmelli
- M. Maffioli
- C. Pascutto
Citations in the corpus
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). (2010, methodology): “The inclusion criteria were (1) diagnosis of PMF based on the presence of megakaryocyte proliferation and atypia accompanied by increased reticulin and/or collagen in bone marrow as major criterion, as well as of the JAK2 (V617F) or the MPL mutations if available and 2 criteria among anemia, splenom”
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. (2008, neutral): “patients with palpable splenomegaly) 2 (2-2)”